Ionis Pharmaceuticals, Inc. (IONS) Market Cap & Valuation Ratios
Ionis Pharmaceuticals, Inc. (IONS) has a market cap of $7.1B and a price-to-sales ratio of 8.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IONSIonis Pharmaceuticals, Inc.Follow IONS — free
—
Price chart with a free account
- Market cap
- 7.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| IONS | 7.1 | — | 7.3 | — | -7.9% | -7% | -68% | -42% |
| CYTK | 8.5 | — | 125.5 | — | -6.8% | -21% | — | -99% |
| TGTX | 8.3 | 19.7 | 10.6 | 62.2 | 0.2% | +76% | 17% | 17% |
| ARWR | 8.2 | — | 11.1 | — | -0.9% | +17% | -34% | -24% |
| SYRE | 8.0 | — | — | — | -2.6% | — | — | -31% |
| AXSM | 7.6 | — | 9.6 | — | -0.9% | +57% | -24% | — |
| PRAX | 7.1 | — | — | — | -4.3% | — | — | -68% |
| IOVA | 6.4 | — | 18.7 | — | -4.6% | +35% | -93% | -51% |
| RYTM | 6.1 | — | 24.7 | — | -1.7% | +54% | -84% | -140% |
| LGND | 6.1 | 32.3 | 20.0 | 45.6 | 2.2% | +55% | 33% | 9% |
| IMVT | 5.9 | — | — | — | -6.9% | — | — | — |
| Median of these 10 | 26.0 | 18.7 | 53.9 | -2.2% | +54% | -29% | -41% |
; EV/Sales 7.3 vs. 18.7.
Growth vs. price
each dot a company · hover or tap for valuesIonis Pharmaceuticals, Inc. — questions
- What is Ionis Pharmaceuticals, Inc.'s market cap?
- $7.1B.
- What is Ionis Pharmaceuticals, Inc.'s price-to-sales ratio?
- 8.2.
Every figure on this page comes from Ionis Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.